Dopamine-Mediated Oxidation of Methionine 127 in α-Synuclein Causes Cytotoxicity and Oligomerization of α-Synuclein

Parkinson's disease (PD) is a neurodegenerative disorder characterized by the selective loss of dopaminergic neurons and the presence of Lewy bodies. Many recent studies focused on the interaction between α-synuclein (α-syn) and dopamine in the pathogenesis of PD, and fluorescent anisotropy suggested that the C-terminal region of α-syn may be a target for modification by dopamine. However, it is not well understood why PD-related pathogenesis occurs selectively in dopaminergic neurons. We investigated the interaction between dopamine and α-syn with regard to cytotoxicity. A soluble oligomer was formed by co-incubating α-syn and dopamine in vitro. To clarify the effect of dopamine on α-syn in cells, we generated PC12 cells expressing human α-syn, as well as the α-syn mutants, M116A, Y125D, M127A, S129A, and M116A/M127A, in a tetracycline-inducible manner (PC12-TetOFF-α-syn). Overexpression of wildtype α-syn in catecholaminergic PC12 cells decreased cell viability in long-term cultures, while a competitive inhibitor of tyrosine hydroxylase blocked this vulnerability, suggesting that α-syn-related cytotoxicity is associated with dopamine metabolism. The vulnerabilities of all mutant cell lines were lower than that of wildtype α-syn-expressing cells. Moreover, α-syn containing dopamine-mediated oxidized methionine (Met(O)) was detected in PC12-TetOFF-α-syn. Met(O) was lower in methionine mutant cells, especially in the M127A or M116A/M127A mutants, but also in the Y125D and S129A mutants. Co-incubation of dopamine and the 125YEMPS129 peptide enhanced the production of H2O2, which may oxidize methionine residues and convert them to Met(O). Y125- or S129-lacking peptides did not enhance the dopamine-related production of H2O2. Our results suggest that M127 is the major target for oxidative modification by dopamine, and that Y125 and S129 may act as enhancers of this modification. These results may describe a mechanism of dopaminergic neuron-specific toxicity of α-syn in the pathogenesis of PD.

[1]  Houeto Jean-Luc.  [Parkinson's disease]. , 2022, La Revue du praticien.

[2]  R. Pfeiffer.  Autonomic dysfunction in Parkinson's disease , 2012, Expert review of neurotherapeutics.

[3]  C. Kusumoto,et al.  Cytoprotective effect of chlorogenic acid against α-synuclein-related toxicity in catecholaminergic PC12 cells , 2012, Journal of clinical biochemistry and nutrition.

[4]  P. Derkinderen,et al.  Parkinson Disease: The Enteric Nervous System Spills its Guts , 2012, Neurology.

[5]  N. Hattori,et al.  Molecular pathogenesis of Parkinson's disease: update , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[6]  Christine Van Broeckhoven,et al.  Parkinson disease: Insights in clinical, genetic and pathological features of monogenic disease subtypes , 2011, Journal of Chemical Neuroanatomy.

[7]  I. Martin,et al.  Recent advances in the genetics of Parkinson's disease. , 2011, Annual review of genomics and human genetics.

[8]  H. Tanila,et al.  Decreased reuptake of dopamine in the dorsal striatum in the absence of alpha-synuclein , 2011, Brain Research.

[9]  S. Cragg,et al.  α-Synuclein and dopamine at the crossroads of Parkinson's disease , 2010, Trends in Neurosciences.

[10]  Marc Cruts,et al.  Genetic Etiology of Parkinson Disease Associated with Mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 Genes: A Mutation Update , 2010, Human mutation.

[11]  V. Uversky,et al.  Methionine oxidation stabilizes non-toxic oligomers of alpha-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions. , 2010, Biochimica et biophysica acta.

[12]  K. Nakashima,et al.  Endogenous catecholamine enhances the dysfunction of unfolded protein response and α-synuclein oligomerization in PC12 cells overexpressing human α-synuclein , 2010, Neuroscience Research.

[13]  Yusuke Nakamura,et al.  Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease , 2009, Nature Genetics.

[14]  B. Hyman,et al.  Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. , 2009, The Journal of clinical investigation.

[15]  D. Moore,et al.  Clearance and Phosphorylation of Alpha-Synuclein Are Inhibited in Methionine Sulfoxide Reductase A Null Yeast Cells , 2009, Journal of Molecular Neuroscience.

[16]  Aj Lees,et al.  Parkinson's disease (vol 373, pg 2055, 2009) , 2009 .

[17]  C. Masters,et al.  Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation. , 2009, Free radical biology & medicine.

[18]  J. Rochet,et al.  Methionine sulfoxide reductase A protects dopaminergic cells from Parkinson's disease-related insults. , 2008, Free radical biology & medicine.

[19]  Nobutaka Hattori,et al.  Progress in the pathogenesis and genetics of Parkinson's disease , 2008, Philosophical Transactions of the Royal Society B: Biological Sciences.

[20]  N. Brot,et al.  Methionine Sulfoxide Reductase A and a Dietary Supplement S-Methyl-L-Cysteine Prevent Parkinson's-Like Symptoms , 2007, The Journal of Neuroscience.

[21]  H. Ischiropoulos,et al.  Cellular Oligomerization of α-Synuclein Is Determined by the Interaction of Oxidized Catechols with a C-terminal Sequence* , 2007, Journal of Biological Chemistry.

[22]  L. Bubacco,et al.  Kinetic and Structural Analysis of the Early Oxidation Products of Dopamine , 2007, Journal of Biological Chemistry.

[23]  K. Beyer.  α-Synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers , 2006, Acta Neuropathologica.

[24]  Thomas C. Südhof,et al.  α-Synuclein Cooperates with CSPα in Preventing Neurodegeneration , 2005, Cell.

[25]  D. Selkoe,et al.  Dopamine covalently modifies and functionally inactivates parkin , 2005, Nature Medicine.

[26]  K. Nakashima,et al.  L‐dopa and dopamine enhance the formation of aggregates under proteasome inhibition in PC12 cells , 2005, FEBS letters.

[27]  V. Uversky,et al.  Methionine oxidation, a-synuclein and Parkinson's disease , 2005 .

[28]  A Dürr,et al.  Causal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.

[29]  Philippe Amouyel,et al.  α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.

[30]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[31]  Bruce A. Yankner,et al.  Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease , 2002, Nature Medicine.

[32]  E. Masliah,et al.  α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.

[33]  Peter T. Lansbury,et al.  Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct , 2001, Science.

[34]  Nobutaka Hattori,et al.  Ubiquitination of a New Form of α-Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease , 2001, Science.

[35]  J. B. Justice,et al.  Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter , 2001, Journal of neurochemistry.

[36]  J. Trojanowski,et al.  Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.

[37]  Sid Gilman,et al.  Widespread Alterations of α-Synuclein in Multiple System Atrophy , 1999 .

[38]  S Gilman,et al.  Widespread alterations of alpha-synuclein in multiple system atrophy. , 1999, The American journal of pathology.

[39]  K. Vrana,et al.  Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase , 1998, Journal of neuroscience research.

[40]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[41]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[42]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[43]  E. Masliah,et al.  Non-A beta component of Alzheimer's disease amyloid (NAC) is amyloidogenic. , 1995, Biochemistry.

[44]  E. Masliah,et al.  Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[45]  R. Scheller,et al.  Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[46]  V. Buchman,et al.  Edinburgh Research Explorer Absence of alpha-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice , 2010 .

[47]  伊藤 悟.  Endogenous catecholamine enhances the dysfunction of unfolded protein response and α-synuclein oligomerization in PC12 cells overexpressing human α-synuclein , 2010 .

[48]  Ikuko Miyazaki,et al.  Dopamine- or L-DOPA-induced neurotoxicity: The role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease , 2009, Neurotoxicity Research.

[49]  T. Südhof,et al.  Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. , 2005, Cell.

[50]  A Dürr,et al.  Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. , 2004, Lancet.

[51]  Philippe Amouyel,et al.  Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. , 2004, Lancet.

[52]  K. Wakabayashi,et al.  Neuropathology of autonomic nervous system in Parkinson's disease. , 1997, European neurology.

[53]  W. Vogt.  Oxidation of methionyl residues in proteins: tools, targets, and reversal. , 1995, Free radical biology & medicine.